| 09/08/22 | 09:30:06 | 9 Aug 2022 | | First Participant in Phase I Trial of IMG-004 |
| 08/08/22 | 09:30:05 | 8 Aug 2022 | | Preliminary results from SAVANNAH Phase 2 Trial |
| 08/08/22 | 07:00:06 | 8 Aug 2022 | | FRESCO-2 Study Has Met Primary Endpoint |
| 01/08/22 | 12:04:30 | 1 Aug 2022 | | Interim Results and Business Updates |
| 01/08/22 | 07:00:12 | 1 Aug 2022 | | HUTCHMED Initiates Bridging Study of Tazemetostat |
| 15/07/22 | 09:30:01 | 15 Jul 2022 | | HUTCHMED Initiates Phase I Trial of HMPL-A83 |
| 13/07/22 | 07:00:07 | 13 Jul 2022 | | Results of SAVANNAH Global Phase II Trial at WCLC |
| 06/07/22 | 07:00:12 | 6 Jul 2022 | | First Participants in Phase I Trial of IMG-007 |
| 30/06/22 | 09:30:06 | 30 Jun 2022 | | Total Voting Rights |
| 29/06/22 | 09:30:06 | 29 Jun 2022 | | Blocklisting Six Monthly Return |
| 27/06/22 | 09:30:01 | 27 Jun 2022 | | HUTCHMED to Announce 2022 Half-Year Results |
| 01/06/22 | 09:30:01 | 1 Jun 2022 | | TAZVERIK® Approved in Hainan Pilot Zone |
| 24/05/22 | 11:00:01 | 24 May 2022 | | LTIP and Share Options |
| 16/05/22 | 12:00:07 | 16 May 2022 | | Appointment of Non–Executive Director |
| 03/05/22 | 07:00:13 | 3 May 2022 | | HUTCHMED Receives CRL from the US FDA |
| 27/04/22 | 14:30:07 | 27 Apr 2022 | | Annual General Meeting Poll Results |
| 21/04/22 | 09:30:01 | 21 Apr 2022 | | Vesting of awards under Long Term Incentive Plan |
| 31/03/22 | 07:00:09 | 31 Mar 2022 | | Update on Status under HFCAA |
| 23/03/22 | 08:30:02 | 23 Mar 2022 | | 2021 Annual Report and Notice of AGM |
| 11/03/22 | 09:00:01 | 11 Mar 2022 | | Update on Status under HFCAA |
| 09/03/22 | 08:30:01 | 9 Mar 2022 | | Vesting of awards under Long Term Incentive Plan |
| 07/03/22 | 07:00:11 | 7 Mar 2022 | | HUTCHMED Receives $15m Milestone from AstraZeneca |
| 03/03/22 | 15:30:07 | 3 Mar 2022 | | Publication of Form 20-F |
| 03/03/22 | 12:30:06 | 3 Mar 2022 | | Retirement of CEO and appointment of new CEO |
| 03/03/22 | 12:00:06 | 3 Mar 2022 | | Full Year Results and Business Updates |
| 01/03/22 | 08:30:01 | 1 Mar 2022 | | Approval to Commercialize ELUNATE® in Macau |
| 07/02/22 | 08:30:02 | 7 Feb 2022 | | HUTCHMED to Announce 2021 Final Results |
| 04/02/22 | 09:30:08 | 4 Feb 2022 | | Phase Ib/II Combination Study of HMPL-453 |
| 20/01/22 | 07:00:09 | 20 Jan 2022 | | HUTCHMED Initiates Phase I Trial of HMPL-653 |
| 19/01/22 | 07:00:08 | 19 Jan 2022 | | HUTCHMED Data at ASCO GI Cancers Symposium |
| 17/01/22 | 09:00:02 | 17 Jan 2022 | | Holding(s) in Company |
| 12/01/22 | 11:00:01 | 12 Jan 2022 | | Breakthrough Therapy Designation for HMPL-523 |
| 10/01/22 | 07:00:10 | 10 Jan 2022 | | HUTCHMED Initiates Phase I Study of HMPL-760 |
| 31/12/21 | 07:00:04 | 31 Dec 2021 | | Blocklisting Six Monthly Return |
| 31/12/21 | 07:00:03 | 31 Dec 2021 | | Total Voting Rights |
| 20/12/21 | 07:00:08 | 20 Dec 2021 | | HUTCHMED Included in FTSE Russell Indexes |
| 15/12/21 | 09:45:01 | 15 Dec 2021 | | Grant of Share Options and Awards under LTIP |
| 14/12/21 | 07:00:11 | 14 Dec 2021 | | HMPL-523 Clinical Data Presented at ASH |
| 10/12/21 | 10:00:01 | 10 Dec 2021 | | HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21 |
| 06/12/21 | 07:00:09 | 6 Dec 2021 | | HUTCHMED Completes Planned Enrollment of FRESCO-2 |
| 03/12/21 | 07:00:04 | 3 Dec 2021 | | Updated NRDL to include ELUNATE and SULANDA |
| 30/11/21 | 08:30:05 | 30 Nov 2021 | | Total Voting Rights |
| 24/11/21 | 07:00:04 | 24 Nov 2021 | | HUTCHMED and AZ Initiate SACHI Phase 3 Trial |
| 08/11/21 | 07:00:09 | 8 Nov 2021 | | HUTCHMED to Present Clinical Data at ASH |
| 01/11/21 | 07:00:14 | 1 Nov 2021 | | HUTCHMED and AZ Initiate SAMETA Global P3 Trial |
| 29/10/21 | 09:30:02 | 29 Oct 2021 | | Total Voting Rights |
| 28/10/21 | 07:00:04 | 28 Oct 2021 | | HUTCHMED Initiates Phase III Trial of HMPL-523 |
| 20/10/21 | 09:30:03 | 20 Oct 2021 | | Grant of Awards under Long Term Incentive Plan |
| 30/09/21 | 09:30:07 | 30 Sept 2021 | | Total Voting Rights |
| 29/09/21 | 07:00:10 | 29 Sept 2021 | | Closure of Non-Core OTC Joint Venture Divestment |
